ClinicalTrials.gg
TerminatedNCT02002689SIGNATUREUpdated May 2, 2016Results posted

LDE225 for Patients With PTCH1 or SMO Mutated Tumors

A Phase 2 interventional study of LDE225 in PTCH1 or SMO Activated Solid and Hematologic Tumors, sponsored by Novartis Pharmaceuticals. Terminated at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-05-02.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Why this study was terminated
Low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies in Basal Cell Nevus Syndrome with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Basal Cell Nevus Syndrome · United States.

Enrollment
15th of 18
10 · median 35
Started
2014
with 1 other
Phase 2
10 of 20
none open now
Registered
8th of 20
by date
Lead sponsor
1 of 20
Novartis Pharmaceuticals

Among the 20 studies in Basal Cell Nevus Syndrome with a site in United States, this one is the 15th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2014, is one of 10 in phase 2, and was the 8th registered.

Basal Cell Nevus Syndrome

35 studies on the registry are indexed under Basal Cell Nevus Syndrome; 4 are open to participants now.

Browse Basal Cell Nevus Syndrome studies →

Open to participants now

1 of the 20 studies in Basal Cell Nevus Syndrome with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 3 Basal Cell Nevus Syndrome studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Basal Cell Nevus Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this signal seeking study is to determine whether treatment with LDE225 demonstrates sufficient efficacy in hedgehog pathway-mutated solid tumors and/or hematologic malignancies to warrant further study

03

Conditions studied

  • PTCH1 or SMO Activated Solid and Hematologic Tumors

Keywords

  • Solid tumor malignancy,
  • hematologic malignancy,
  • mutation, translocations,
  • signature,
  • PTCH1,
  • SMO,
  • LDE225,
  • endometrial cancer,
  • colon cancer,
  • bladder,
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has confirmed diagnosis of a select solid tumor (except medulloblastoma, basal cell carcinoma and pancreatic adenocarcinoma) or hematological (except CML, ALL and AML).
  • Patient has pre-identified tumor with a PTCH1 or SMO mutation.
  • Patient has received at least one prior treatment for recurrent, and /or locally advanced disease and for whom no standard therapy options are anticipated to result in a durable remission.
  • Patient has progressive and as per 1.1. or other appropriate hematological guidelines.
  • Patient has an (ECOG) performance status ≤ 1

Exclusion criteria

Exclusion Criteria:

  • Patients has received prior treatment with LDE225.
  • Patients has neuromuscular disorders associated with elevated CK (i.e. inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis and spinal muscular atrophy) or are on concomitant treatment with drugs that are recognized to cause rhabdomyolysis
  • Patients has primary CNS tumor or CNS tumor involvement
  • Patient has received chemotherapy or anticancer therapy ≤ 4 weeks prior to starting study drug
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    LDE225

    LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule.

    Drug: LDE225

Interventions

  • DrugLDE225

    LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule

06

What researchers measure

Primary outcomes

  1. Summary of Overall Response (ORR) and Clinical Benefit (CBR)

    Clinical benefit rate (CBR) Number and percentage of subjects with CBR (responses of CR, PR or SD ≥ 16 weeks) as assessed by investigator was reported for all patients along with 95% exact confidence interval (CI). Overall Response Rate (ORR) Overall response was to be determined by investigator assessment for each tumor in the study. For subjects with solid tumors, the assessment criteria was RECIST 1.1 and included responses of CR and/or PR. The number and percentage of subjects for different categories of overall response (e.g., for solid tumors - CR, PR, SD, PD, Not Evaluable) were to be provided for solid tumors, and each hematological tumor type (if applicable). Ninety-five percent (95%) exact CI was to be provided for the response rate(s) (e.g., for solid tumors - CRn and/or PR) as well.

    Time frame: 16 weeks

Secondary outcomes

  1. Summary of Timing and Estimated Rate for Progression-free Survival (PFS) - Full Analysis Set

    Progression-free survival (PFS) is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause within 30 days of last dose. If a subject has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.

    Time frame: 4 months

  2. Kaplan-Meier Estimates of Progression Free Survival (PFS )Timing, Months

    Time frame: 4 months

07

Results

Posted May 2, 2016
Limitations and caveats
The study was closed for accrual when the sponsor realized that not enough patients will be recruited for any meaningful stat analysis even if the study were kept open beyond the original planned accrual window.

Participant flow

The study was closed for accrual when the sponsor realized that not enough patients will be recruited for any meaningful stat analysis even if the study were kept open beyond the original planned accrual window.

Participant flow — Overall Study
MilestoneSonidegib
Started10
Completed0
Not completed10
Withdrew: Disease progression7
Withdrew: Adverse event3

Outcome measures

PrimarySummary of Overall Response (ORR) and Clinical Benefit (CBR)

Clinical benefit rate (CBR) Number and percentage of subjects with CBR (responses of CR, PR or SD ≥ 16 weeks) as assessed by investigator was reported for all patients along with 95% exact confidence interval (CI). Overall Response Rate (ORR) Overall response was to be determined by investigator assessment for each tumor in the study. For subjects with solid tumors, the assessment criteria was RECIST 1.1 and included responses of CR and/or PR. The number and percentage of subjects for different categories of overall response (e.g., for solid tumors - CR, PR, SD, PD, Not Evaluable) were to be provided for solid tumors, and each hematological tumor type (if applicable). Ninety-five percent (95%) exact CI was to be provided for the response rate(s) (e.g., for solid tumors - CRn and/or PR) as well.

Time frame:
16 weeks
Reported as:
Number · percent responders
Summary of Overall Response (ORR) and Clinical Benefit (CBR)
percent respondersSonidegib
Complete response (CR)0
Partial response (PR)0
Stable disease (SD)0
Progressive disease (PD)8
Non-evaluable (NE)2
Overall response rate (ORR: CR+PR)0
Clinical benefit rate (CBR: CR+PR+SD)0
SecondarySummary of Timing and Estimated Rate for Progression-free Survival (PFS) - Full Analysis Set

Progression-free survival (PFS) is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause within 30 days of last dose. If a subject has not had an event, progression-free survival is censored at the date of last adequate tumor assessment.

Time frame:
4 months
Reported as:
Number · % progression free surviors
Summary of Timing and Estimated Rate for Progression-free Survival (PFS) - Full Analysis Set
% progression free surviorsSonidegib
1 Month88.9 (43.3 to 98.4)
2 Months33.3 (7.8 to 62.3)
3 Months33.3 (7.8 to 62.3)
4 Months0.0 (NA to NA)
SecondaryKaplan-Meier Estimates of Progression Free Survival (PFS )Timing, Months
Time frame:
4 months
Reported as:
Median · months
Kaplan-Meier Estimates of Progression Free Survival (PFS )Timing, Months
monthsSonidegib
Kaplan-Meier Estimates of Progression Free Survival (PFS )Timing, Months1.8 (0.9 to 3.6)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDE225—7/10 (70%)10/10 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventLDE225
Abdominal painGastrointestinal disorders2/10
DehydrationMetabolism and nutrition disorders2/10
DysphagiaGastrointestinal disorders1/10
Small intestinal obstructionGastrointestinal disorders1/10
PneumoniaInfections and infestations1/10
Failure to thriveMetabolism and nutrition disorders1/10
Muscular weaknessMusculoskeletal and connective tissue disorders1/10
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/10
CoughRespiratory, thoracic and mediastinal disorders1/10
DysphoniaRespiratory, thoracic and mediastinal disorders1/10
Most frequent other events
Showing 10 of 46
Most frequent other events
EventLDE225
NauseaGastrointestinal disorders8/10
FatigueGeneral disorders6/10
Decreased appetiteMetabolism and nutrition disorders5/10
VomitingGastrointestinal disorders4/10
Weight decreasedInvestigations4/10
ConstipationGastrointestinal disorders3/10
DiarrhoeaGastrointestinal disorders3/10
Urinary tract infectionInfections and infestations3/10
Alanine aminotransferase increasedInvestigations3/10
Aspartate aminotransferase increasedInvestigations3/10

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Sonidegib
<=18 years0
Between 18 and 65 years4
>=65 years6
Age, Continuous
Age, Continuous(years)Sonidegib
Mean63.2 ± 7.64
Sex: Female, Male
Sex: Female, Male(Participants)Sonidegib
Female6
Male4
08

Study locations

10 sites
  • University of California Davis Cancer Center UC Davis Cancer (3)
    Sacramento, California 95817, United States
  • Rocky Mountain Cancer Centers RMCC - Aurora
    Greenwood Village, Colorado, United States
  • Lurie Children's Hospital of Chicago Developmental Therapeutics
    Chicago, Illinois 60611, United States
  • Minnesota Oncology Hematology, P.A. Southdate Medical Center
    Minneapolis, Minnesota 55404, United States
  • Cleveland Clinic Foundation Cleveland Clinic (19)
    Cleveland, Ohio 44195, United States
  • Sanford Research Sanford Health
    Sioux Falls, South Dakota 57104, United States
  • Oncology Consultants Oncology Group
    Houston, Texas 77024, United States
  • MD Anderson Cancer Center/University of Texas MD Anderson Cancer Center (3)
    Houston, Texas 77030, United States
  • Intermountain Medical Center Intermountain Healthcare
    Murray, Utah 84157, United States
  • Seattle Cancer Care Alliance Skagit Valley Hospital
    Seattle, Washington 98109-1023, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of Mar 2015 and a completion of Mar 2015. It does not say whether these dates are actual or estimated.

Results were first posted in May 2016, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2013
First posted
Dec 6, 2013
Start
Feb 2014
Primary completionActual
Mar 2015
CompletionActual
Mar 2015
Results first posted
May 2, 2016
Last update
May 2, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02002689
Responsible party
Sponsor
First posted
Dec 6, 2013
Start date
Feb 2014
Primary completion
Mar 2015
Completion
Mar 2015
Results posted
May 2, 2016
Last update
May 2, 2016

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sonidegib

Start the discussion